The ICH Q1A (R2) guideline outlines the stability testing requirements for new drug substances and products to ensure they maintain their quality, safety, and efficacy
over time. It provides detailed guidance on the design of stability studies, specifying the conditions under which testing should be conducted, such as temperature, humidity, and light exposure. These studies help to determine the drug’s shelf life and recommended storage conditions. Long-term, accelerated, and intermediate testing conditions are suggested based on the product’s characteristics and intended market.
Stability testing involves periodic analysis of the physical, chemical, and microbiological attributes of the product. Additionally, the guideline emphasises the importance of testing in different packaging and container-closure systems to ensure compatibility and prevent degradation. For certain climates, special provisions apply under climatic zone considerations, which include zones I-IV based on global climate differences. Stress testing is also recommended to identify degradation pathways and validate analytical methods used for stability assessment. This approach ensures a scientific basis for defining shelf life and the expiration date, ensuring that the drug product remains safe and effective for patients throughout its market life. 
The ICH Q1D guideline introduces a bracketing and matrixing design for stability testing, allowing reduced testing by selecting representative samples from the full set of products. This strategy saves time and resources without compromising the integrity of the stability studies or the quality assessment of the drug product.